Researchers report that a very low dose of estrogen might help women whose metastatic breast cancer appears again after treatment.
According to the research, if estrogen lowering drugs no longer control metastatic breast cancer, the opposite strategy might work.
It was found that 30% women with metastatic breast cancer, who no longer responded to routine anti-estrogen treatment, benefited from raising estrogen levels.
Dr. Matthew Ellis of Washington University School of Medicine in St. Louis and colleagues studied 66 women with advanced breast cancer who had been treated with newer drugs called aromatase inhibitors. They include Pfizer’s Aromasin, Novartis’s Femara, and AstraZeneca Plc’s Arimidex.
Read full report on Washington University School of Medicine
